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HTA is considered the most comprehensive and transparent method 
of supporting decision-makers in their choices in Public Health.
HTA on vaccines is being performed by many experts. However, 
they often present their studies to colleagues, but not to decision-
makers, who should be the main target and current users. It is 
therefore crucial to improve the transfer of scientific data to deci-
sion-makers and all stakeholders.
The aims of the present project are: 1) to set up a team of experts 
to collect economic evaluations and HTA studies on vaccines 
and assess their actual use in decision-making processes; 2) to 
constitute regional working groups in order to identify the criti-
cal aspects of the communication process and identify the most 
appropriate method of data transfer.
Systematic reviews of economic evaluations and HTA on 
vaccines and their actual use in decision-making will be 
used to draw up the basic documents for discussion by the 
3 regional working boards. The working groups will discuss 
the current scientific evidence and communication methods 
and will try to implement a model of technology assessment 
with well-defined and objective criteria, in order to better 
fit pharmaco-economic and HTA methods to the field of vac-
cinations.
Improving the transfer of HTA results to stakeholders, particu-
larly decision-makers, will enable decisions to be taken on the 
basis of scientific evidence, and appropriate, sustainable actions 
to be undertaken.
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Introduction 
In accordance with the recommendations of the World 
Health Organization (WHO) (2005)  [1], the current 
Italian National Plan for Vaccination Prevention 2012-
2014 (PNPV) [2] specifies that the choices made in the 
sector of prevention, such as those concerning vaccina-
tion, should be based on clear, robust, shared criteria. 
This need is due to the increasing availability of new 
vaccines, the introduction of new vaccination indica-
tions and the limited economic resources of health sys-
tems, even in developed countries. Only by prioritizing 
all possible preventive interventions can we rational-
ize the use of limited resources and maximize results 
in terms of health. As Health Technology Assessment 
(HTA) meets the above-mentioned criteria, it may con-
stitute the best approach to this issue. 
HTA is regarded as the most comprehensive and trans-
parent method of supporting decision-makers in their 
choices concerning health technologies. This approach 
is even more important in the Public Health sector, par-
ticularly with regard to vaccine prevention  [3]. As vac-
cination targets healthy individuals, its benefits (such as 
absence of disease, reduced disease burden etc.) are often 
unapparent to both the population and decision-makers. 
Consequently, preventive interventions are viewed only 
as a considerable cost to the health system, rather than 
as fundamental investments that generate benefits in the 
short and long terms. These issues are even more evi-
dent today, in the current critical period of spending re-
view in Italy. Indeed, the most debated issue related to 
the introduction of a new vaccine is that of economic 
sustainability. In order to verify economic sustainability, 
pharmaco-economic evaluations are needed. The first 
step in this process is to evaluate the costs that a disease 
generates for the National Health Service (point of view 
of the third-party payer) and the community (point of 
view of society). Pharmaco-economics offers several ap-
proaches. In the field of vaccinations, the most frequently 
used approach is cost-effectiveness analysis, whereby the 
cost of vaccination is compared with its clinical benefit 
(e.g. the number of cases avoided or the years of sur-
vival gained). Among cost-effectiveness analyses, cost-
utility analysis is preferentially adopted, as benefits are 
measured in QALYs (quality-adjusted life-years). When 
comparing two or more alternatives which have different 
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costs and degrees of efficacy/effectiveness, it is important 
to obtain information in a single summary measure, i.e. 
considering both cost and effectiveness. The Incremental 
Cost-effectiveness Ratio (ICER) provides this information 
and expresses the additional cost of each unit of a health 
outcome (e.g. one QALY) obtained by one strategy com-
pared with another. The ICER is a fundamental parameter 
for decision-makers. However, decision-makers must also 
consider other domains: the epidemiology of the disease 
in question; vaccine efficacy/effectiveness; the predicted 
clinical impact on the population, as assessed through 
mathematical modelling of possible vaccination strate-
gies; ethical, social and legal aspects, and the impact of 
introducing a new vaccine on health organizations. HTA 
deals with all these aspects.
In Italy, as in other countries, the application of HTA to 
vaccines has increased in recent years. Many HTA reports 
and pharmaco-economic studies, including several in the 
Italian context, have been published  [4-24]. Although 
the data from these studies are widely available, they are 
often underused by decision-makers, who may lack the 
knowledge and ability necessary to exploit them fully. In-
deed, decision-makers often evaluate the implementation 
of new vaccines only on the basis of vaccination costs, 
without considering the clinical and economic benefits 
derived from the avoidance of cases of disease.
It is therefore essential to improve the transfer of scien-
tific data to decision-makers and all stakeholders, in order 
to promote evidence-based decisions in the area of immu-
nization. The introduction of a new vaccine can only be 
based on Evidence-Based Medicine (EBM), or rather Evi-
dence-Based Prevention (EBP) [25]. To achieve this goal, 
it is necessary to create a communication network linking 
all subjects involved in the decisional process: research-
ers, decision-makers and stakeholders. In this perspective, 
the project “HTA for public health decision-makers in the 
area of vaccination” has been planned and endorsed by 
the ISPOR Rome Chapter.
The International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR), founded in 1995, is a pub-
lic non-profit educational and scientific association. It 
promotes pharmaco-economic and outcome research 
and facilitates the translation of the results of that re-
search into useful information for decision-makers in 
order to encourage efficiency, effectiveness and equity 
in health and to improve the health of the population. 
The ISPOR Italy-Rome Chapter is a working group af-
filiated to ISPOR and sharing its mission and objectives. 
It involves healthcare professionals, providers of health-
care technologies, decision-makers and other pertinent 
subjects in issues of pharmaco-economics and outcome 
research in the Italian context.
Objectives
The objectives of the project are:
1)  to organize a multidisciplinary working group com-
posed of experts (the Project’s founding group) in 
order to: 
•	 carry out systematic reviews of economic evalu-
ations and HTA reports on vaccines and vaccina-
tion strategies;
•	 assess the current use of HTA and economic eval-
uations in decision-making processes;
•	 implement a model of technology assessment 
with well-defined and objective criteria, in order 
to better fit pharmaco-economic and HTA meth-
ods to the field of vaccinations.
2)  to constitute regional working groups composed of 
experts, decision-makers and stakeholders in order 
to:
•	 identify and define critical points in communica-
tion from/to decision-makers and stakeholders 
and in data transfer processes, in order to identify 
the most appropriate method of data transfer;
•	 increase decisions taken on the basis of scientific 
evidence in the field of vaccinations;
•	 improve the culture of vaccination in the Italian 
population and counteract the spread of errone-
ous, confusing and outdated information.
Achievement of these objectives will lead to the identi-
fication of the best strategies for creating a “data bridge” 
between researchers, decision-makers and stakeholders.
Materials and methods 
Two different main activities will be performed: sys-
tematic reviews of economic and HTA studies on vac-
cine/vaccination strategies, and organization of working 
boards. Table I shows the main activities of the ISPOR 
Rome Chapter Project.
The following specific activities will be carried out:
•	 systematic reviews of economic and HTA evalua-
tions of vaccination strategies or of vaccines already 
included in the Italian vaccination schedule or still 
under discussion for inclusion in the current regional 
or national vaccination programs: for example, HPV 
vaccination in females and males, meningococcal C 
vaccine, pneumococcal vaccine in children and the 
elderly, varicella vaccine, quadrivalent conjugate 
meningococcal vaccine, meningococcal B vaccine, 
rotavirus vaccine, and herpes zoster vaccine. This 
systematic review will be performed on PubMed, 
Scopus and NIHR HTA databases; articles published 
at any time up to the end of 2015 will be included. 
PubMed and Scopus will be queried by means of a 
combination of MESH terms and keywords referring 
to vaccines/vaccinations and HTA/economic evalu-
ations, while the search on NIHR HTA will be per-
formed through the use of keywords related only to 
vaccines/vaccinations. Furthermore, a hand-search 
of the following journals will be carried out: Global 
& Regional Health Technology Assessment, Phar-
maco-Economics Italian Research Articles, Giornale 
Italiano di HTA, Politiche Sanitarie, HTA Focus – 
Pills of Clinical Governance, Pillole di Farmaco-
economia, Giornale Italiano di Farmacoeconomia 
e Farmacoutilizzazione, Italian Journal of Public 
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Health and Quaderni dell’Italian Journal of Public 
Health. Eligible articles will be identified through a 
two-step approach: screening of titles/abstracts and 
reading of full texts. Articles will be considered eli-
gible if they report the results of an economic evalu-
ation or of an HTA performed in Italy or one or more 
Italian Region;
•	 evaluation of the real use of economic and HTA 
studies in the decision-making process in Italy in 
recent years. This evaluation will be performed by 
comparing the results of the studies collected with 
the decisions taken at the national and regional levels 
in recent years, with regard to the inclusion of new 
vaccines or vaccination strategies in immunization 
programmes;
•	 some vaccination programmes will be compared 
with other health interventions (therapeutic interven-
tions) by means of mathematical models, in order to 
increase decision-makers’ awareness of the fact that 
investments in the field of vaccines generate signifi-
cant benefits and are not only a cost for the health 
system. For example, HPV vaccination in females 
will be compared with therapeutic interventions in 
women with HPV-related lesions/cancer.
These activities will be carried out by the Project’s 
“founding group”, made up of researchers working on 
these subjects at the Universities of Florence, Genoa and 
Rome (Catholic University and Tor Vergata Universi-
ty). The founding group will also implement a model of 
technology assessment with well-defined and objective 
criteria, in order to better fit pharmaco-economic and 
HTA methods to the field of vaccinations.
Data acquired from these activities will be used to draw 
up the basic documents for discussion by the working 
boards that will be organized. The working boards will 
be composed of all relevant subjects involved in the 
decision-making process: researchers, decision makers 
and stakeholders. (Tab. II). The parties that have an in-
terest are: citizens and their associations, health profes-
sionals and their associations, scientific societies, those 
elected by citizens to the various levels of government, 
businesses and no-profit partners, academics, and volun-
teers and their associations [26].
The importance of involving as many stakeholders as 
possible stems from the need to improve the culture of 
vaccination in the Italian population and to counteract 
the spread of erroneous, confusing and outdated informa-
tion. Indeed, the success of a vaccination campaign de-
pends not only on the supply of a vaccine free of charge, 
but also on the acceptance of vaccination on the part of 
the target population. The acceptability of vaccination 
strongly influences vaccine coverage rates, and only 
high vaccine coverage enables the incidence of disease 
to be reduced, thereby achieving considerable savings in 
terms of both healthcare and socioeconomic costs. Opin-
ion leaders and journalists will be involved in the work-
ing groups, on account of their significant influence on 
the choices of the population and decision-makers. In 
particular, journalists can support the improvement of 
communication between researchers and decision-mak-
ers by identifying the most appropriate method of data 
transfer. Journalists can also help to spread the culture of 
vaccination in the population and increase public aware-
ness of the importance of prevention activities.
Tab. I. The main activities of ISpOr rome Chapter project.
Activities Working boards
Systematic reviews on economic and hTA evaluations of vaccination strategies or vaccines already 
included in the vaccination schedule in Italy and europe.
project’s founding group
Systematic reviews on economic and hTA evaluations for vaccination strategies or vaccines that are 
as yet under discussion for inclusion in the current regional or national vaccination programs in Italy 
and europe.
project’s founding group
report on the real use of economic and hTA studies in decision-making process in Italy. project’s founding group
development of mathematical models for compared some vaccination programmes with other 
health interventions.
project’s founding group
Identification of critical points in communication from/to decision-makers and stakeholders and in 
data transfer processes in order to identify the most appropriate method of data transfer.
regional working groups
Increasing of decisions taken on the basis of scientific evidence in the field of vaccinations. regional working groups
Improving of the culture of vaccination in the Italian population and counteracting the spread of er-
roneous, confusing and outdated information.
regional working groups
Implementation of a model of technology assessment with well-defined and objective criteria in order 
to better fit pharmaco-economic and hTA methods to the field of vaccinations.
project’s founding group
National event of working groups
Tab. II. multidisciplinary working groups of ISpOr rome Chapter project.
researchers
University researchers
Independent researchers
decision-maker
minister of health
Institute of health
regions
minister of economic
Italian medicine Agency
minister of University
Stakeholders
vaccine manufacturers
Scientific Societies
medical Federations
Citizens associations
provident Institution
volunteers associations
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Expected results and discussion
Two systematic reviews will be published: the first will 
focus on economic and HTA evaluations of vaccination 
strategies or vaccines already included in vaccination 
schedules in Italy and Europe; the second will focus on 
economic and HTA evaluations of vaccination strategies 
or vaccines that are as yet under discussion for inclusion 
in current regional or national vaccination programs in 
Italy and Europe.
A report on the real use of economic and HTA studies 
in the decision-making process in Italy in recent years 
will be made.
Three permanent regional working boards will be set up 
in Northern, Central and Southern Italy, coordinated by 
the Project’s “founding group”. These will discuss the 
current scientific evidence of cost-effectiveness and the 
cost-benefit profiles of vaccinations and will also inves-
tigate other domains relevant to the decisional process 
(such as ethical, social and legal aspects and the impact 
of introducing a new vaccine on health organizations). 
They will also identify and analyse critical points in the 
different kinds of communication, in order to pick out 
the most appropriate methods of communication and da-
ta transfer. Furthermore, they will discern the informa-
tion needs of each subject involved and work out how to 
improve the transfer of knowledge from researchers to 
decision-makers and stakeholders. The information ob-
tained by these permanent regional boards may be vali-
dated in other Italian Regions. Lastly, a national event 
will be organized in order to extend the indications and 
information obtained at the regional level to the national 
level.
The feasibility of the project is guaranteed by the partici-
pation of academics and researchers in the permanent re-
gional working boards. However, the achievement of the 
above-mentioned objectives might be jeopardised by the 
potentially scant participation of decision-makers and 
stakeholders in the communication network. To avoid 
this eventuality, every effort will be made to convince 
decision-makers and stakeholders of the importance of 
developing a communication network with scientific 
experts in order to foster evidence-based decisions that 
meet the needs highlighted by the decision-makers and 
stakeholders themselves.
Finally, individuation of a model of technology assess-
ment with well-defined and objective criteria could con-
tribute to the development of new HTA reports accord-
ing to the requirements and needs evinced by the deci-
sion-makers and stakeholders themselves in the future.
Conclusions
The success of the project will pave the way towards 
an interactive dialogue among all subjects involved in 
the decision-making process. In this way, decisions can 
be taken on the basis of scientific evidence, and appro-
priate, sustainable actions can be undertaken. Indeed, 
healthcare priorities can only be established through 
broadly based, shared evaluations of health interven-
tions. This approach will ensure a more appropriate use 
of limited resources and enable preventive activities that 
generate many benefits and not only costs.
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